NASDAQ:TMCI

Treace Medical Concepts (TMCI) Stock Price, News & Analysis

$4.38
-0.05 (-1.13%)
(As of 05/10/2024 ET)
Today's Range
$4.33
$4.77
50-Day Range
$4.17
$13.74
52-Week Range
$3.92
$27.70
Volume
3.90 million shs
Average Volume
342,645 shs
Market Capitalization
$270.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.57

Treace Medical Concepts MarketRank™ Stock Analysis

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
209.8% Upside
$13.57 Price Target
Short Interest
Bearish
6.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.45mentions of Treace Medical Concepts in the last 14 days
Based on 25 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.91) to ($0.79) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.74 out of 5 stars

Medical Sector

422nd out of 921 stocks

Surgical & Medical Instruments Industry

56th out of 98 stocks

TMCI stock logo

About Treace Medical Concepts Stock (NASDAQ:TMCI)

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

TMCI Stock Price History

TMCI Stock News Headlines

Treace Medical Concepts (NASDAQ:TMCI) PT Lowered to $16.00
The Crypto 9-5 Escape Plan
A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.
The Crypto 9-5 Escape Plan
A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.
Treace Announces First Annual National Bunion Day
7 Stable Stocks for 50% Returns by Early 2025
Treace Medical Concepts Inc
See More Headlines
Receive TMCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/07/2024
Today
5/10/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:TMCI
Fax
N/A
Employees
516
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.57
High Stock Price Target
$27.50
Low Stock Price Target
$5.50
Potential Upside/Downside
+204.3%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

Net Income
$-49,530,000.00
Pretax Margin
-26.47%

Debt

Sales & Book Value

Annual Sales
$187.12 million
Book Value
$2.24 per share

Miscellaneous

Free Float
46,668,000
Market Cap
$275.45 million
Optionable
Optionable
Beta
0.37
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. John T. TreaceMr. John T. Treace (Age 52)
    CEO, Founder & Director
    Comp: $1.09M
  • Mr. Mark L. Hair CPA (Age 54)
    Chief Financial Officer
    Comp: $599.7k
  • Mr. Aaron J. Berutti (Age 45)
    Senior Vice President of Sales
    Comp: $484.22k
  • Mr. Terry W. Lubben (Age 59)
    Senior Vice President of Operations
  • Ms. Julie D. Dewey (Age 63)
    Chief Communications & Investor Relations Officer
  • Mr. Scot M. Elder J.D. (Age 49)
    Chief Legal & Compliance Officer and Corporate Secretary
  • Mr. Nathan Minnich
    Senior Vice President of Marketing
  • Mr. Daniel E. Owens (Age 52)
    Chief Human Resources Officer
  • Dr. Sean F. Scanlan Ph.D. (Age 42)
    Chief Innovation Officer
  • Ms. Shana Zink
    Senior Vice President of Clinical Affairs, Medical Education & Reimbursement

TMCI Stock Analysis - Frequently Asked Questions

Should I buy or sell Treace Medical Concepts stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TMCI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TMCI, but not buy additional shares or sell existing shares.
View TMCI analyst ratings
or view top-rated stocks.

What is Treace Medical Concepts' stock price target for 2024?

7 Wall Street analysts have issued 1-year target prices for Treace Medical Concepts' stock. Their TMCI share price targets range from $5.50 to $27.50. On average, they anticipate the company's stock price to reach $13.57 in the next year. This suggests a possible upside of 209.8% from the stock's current price.
View analysts price targets for TMCI
or view top-rated stocks among Wall Street analysts.

How have TMCI shares performed in 2024?

Treace Medical Concepts' stock was trading at $12.75 on January 1st, 2024. Since then, TMCI shares have decreased by 65.6% and is now trading at $4.38.
View the best growth stocks for 2024 here
.

When is Treace Medical Concepts' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our TMCI earnings forecast
.

How were Treace Medical Concepts' earnings last quarter?

Treace Medical Concepts, Inc. (NASDAQ:TMCI) issued its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.30) EPS for the quarter, hitting the consensus estimate of ($0.30). The business had revenue of $51.11 million for the quarter, compared to the consensus estimate of $49.07 million. Treace Medical Concepts had a negative trailing twelve-month return on equity of 33.96% and a negative net margin of 26.47%. The business's revenue for the quarter was up 21.1% compared to the same quarter last year. During the same period last year, the business earned ($0.23) earnings per share.

What ETF holds Treace Medical Concepts' stock?

iShares U.S. Medical Devices ETF holds 289,221 shares of TMCI stock, representing 0.06% of its portfolio.

What guidance has Treace Medical Concepts issued on next quarter's earnings?

Treace Medical Concepts updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $201.0 million-$211.0 million, compared to the consensus revenue estimate of $222.8 million.

When did Treace Medical Concepts IPO?

Treace Medical Concepts (TMCI) raised $150 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.

Who are Treace Medical Concepts' major shareholders?

Treace Medical Concepts' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.97%), William Blair Investment Management LLC (3.77%), TimesSquare Capital Management LLC (2.24%), Wealth Enhancement Advisory Services LLC (0.39%), Oak Ridge Investments LLC (0.20%) and GSA Capital Partners LLP (0.11%). Insiders that own company stock include Aaron Berutti, Daniel E Owens, F Barry Bays, James T Treace, John R Treace, John T Treace, Mark Hair, Richard W Mott, Scot Michael Elder, Sean F Scanlan, Terry W Lubben and Thomas E Timbie.
View institutional ownership trends
.

How do I buy shares of Treace Medical Concepts?

Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TMCI) was last updated on 5/10/2024 by MarketBeat.com Staff

From Our Partners